Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Inidascamine

Add links
From Wikipedia, the free encyclopedia

Inidascamine
Clinical data
Other namesRL-007; RL007; FSV7-007
Routes of
administration		Oral[1][2]
Identifiers
  • (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N3O2
Molar mass235.287 g·mol−1
3D model (JSmol)
  • C1CCN(C1)C(=O)[C@@H]([C@H](C2=CC=NC=C2)O)N
  • InChI=1S/C12H17N3O2/c13-10(12(17)15-7-1-2-8-15)11(16)9-3-5-14-6-4-9/h3-6,10-11,16H,1-2,7-8,13H2/t10-,11+/m1/s1
  • Key:GRZMKKUGHIECFK-MNOVXSKESA-N

Inidascamine (INNTooltip International Nonproprietary Name; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS).[1][3][4][5][6][2] It is taken orally.[1][2] The drug is said to act on the cholinergic, NMDA, and GABAB receptor systems.[1][5][2] Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences.[1][3] It was discovered via screening of compounds for effects on synaptic plasticity and cognition.[2] The drug shows structural similarities to phenethylamines and amphetamines.[7]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 "RL 007". AdisInsight. 10 June 2024. Retrieved 26 February 2025.
  2. 1 2 3 4 5 Donello JE, Walker GA, Schweighoffer F, and Pando MP. Abstract Number: 149. RL-007, a novel oral neuromodulator, enhances synaptic plasticity and cognition in non-clinical models. American College of Neuropsychopharmacology (ACNP) annual meeting. December 5, 2023. https://ir.atai.life/static-files/06c60339-e93c-42fc-9323-c0e38e83f86e
  3. 1 2 "Delving into the Latest Updates on RL-007 with Synapse". Synapse. 23 January 2025. Retrieved 26 February 2025.
  4. ↑ Brady LS, Lisanby SH, Gordon JA (2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555. PMID 37352473.
  5. 1 2 Vita A, Barlati S, Cavallaro R, Mucci A, Riva MA, Rocca P, et al. (2024). "Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations". Frontiers in Psychiatry. 15 1451832. doi:10.3389/fpsyt.2024.1451832. PMC 11450451. PMID 39371908.
  6. ↑ Ye N, Wang Q, Li Y, Zhen X (March 2025). "Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities". Medicinal Research Reviews. 45 (2): 755–787. doi:10.1002/med.22086. PMID 39300769.
  7. ↑ "2-Amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one, (2R,3S)-". PubChem. Retrieved 26 February 2025.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Inidascamine&oldid=1358175134"